文献速递慢性肾脏病血液净化与透析

格拉瑞韦联合艾尔巴韦治疗HCV基因1或4型合并4/5期慢性肾病患者安全有效

Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.
PubMed 文献 · Kidney Int · 2018-05-05

该研究为多中心、非随机、全国性观察性调查,纳入93例HCV基因1或4型合并重度慢性肾病(70例G5期,其中74.2%接受血透;23例G4期)患者,给予格拉瑞韦/艾尔巴韦(100/50 mg)每日一次。90例可评估患者中87例获得持续病毒学应答12周(SVR12),严重不良事件6例(3例死亡,与治疗无关)。

要点

  • 格拉瑞韦/艾尔巴韦在HCV基因1或4型合并4/5期CKD患者中SVR12达87/90。
  • 严重不良事件6例,3例死亡与治疗无关。
  • 多数患者合并用药多(平均7.7种),需关注药物相互作用。

核心结论

  • 每日一次格拉瑞韦联合艾尔巴韦在HCV基因1或4型合并晚期慢性肾病的难治人群中高效且不良事件率低。

研究设计与样本

  • 非随机、多中心、全国性观察性调查,纳入93例HCV基因1或4型合并晚期慢性肾病患者。

主要发现

  • 90例可评估患者中87例获得SVR12,2例病毒学突破,1例停药后复发。
  • 严重不良事件6例,包括3例死亡,均与格拉瑞韦/艾尔巴韦治疗无关。
  • 患者平均合并用药7.7种。

关键数值与推荐

  • 70例为CKD G5期(其中74.2%接受血透),23例为G4期;33例存在严重肝病(Metavir F3/F4)。
  • 格拉瑞韦/艾尔巴韦剂量为100/50 mg每日一次。

临床怎么用

  • 对于HCV基因1或4型合并4/5期CKD(含血透)患者,可考虑格拉瑞韦/艾尔巴韦每日一次方案。
  • 治疗期间需关注合并用药(平均7.7种)及严重不良事件。

局限性

  • 为非随机观察性调查,样本量有限(93例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with advanced chronic kidney disease who receive direct-acting antiviral drugs require special consideration regarding comorbid conditions. Here we assessed the efficacy and safety of grazoprevir plus elbasvir in 93 patients infected with HCV genotype 1 or 4 and with advanced chronic kidney disease in a non-randomized, multicenter, nationwide observational survey. Twenty patients with HCV genotype 1a, 51 patients with 1b, four unclassified genotype 1, 17 with genotype 4 and one with genotype 6 received grazoprevir plus elbasvir (100/50 mg) once daily. All patients had severe chronic kidney disease with 70 patients stage G5, including patients on hemodialysis (74.2%), and 23 were stage G4 chronic kidney disease. Severe liver disease (Metavir F3/F4) was found in 33 patients. A sustained virologic response 12 weeks after the end of therapy was achieved in 87 of 90 patients. Two patients had a virologic breakthrough and one had a relapse after treatment withdrawal. Most patients received many concomitant medications (mean 7.7) related to comorbid conditions. Serious adverse events occurred in six patients, including three deaths while on grazoprevir plus elbasvir, not related to this therapy. Thus, once-daily grazoprevir plus elbasvir was highly effective with a low rate of adverse events in this advanced chronic kidney disease difficult-to-treat population with an HCV genotype 1 or 4 infection.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Alric L, Ollivier-Hourmand I, Bérard E, et al. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney Int. 2018. PMID: 29735308. doi:10.1016/j.kint.2018.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。